

Design, Molecular Modelling Studies on Isatin Analogues as Novel Inhibitors of HIV Integrase

P. Selvam^{1,*}, M. Chandramohan², N. Saravanan Prabhu³, M. Suresh Kumar³

¹ Devaki Amma Memorial College of Pharmacy, Chelembra, Malapuram, Kerala, India; ² Bharat Ratna Kamarajar Liver Hospital and Research Centre, Madurai 625020, India; ³ Centre for Bioinformatics, School of Life Sciences, Pondicherry University, Puducherry 605014, India

HIV is a member of lentivirus genus, which belongs to retrovirus family and it is single-stranded, positive-sense, enveloped RNA virus leads to the most dreadful disease AIDS. Reverse transcriptase, integrase and protease are the three enzymes which are used as a drug target for the HIV treatment. Among these targets, HIV integrase is the enzyme responsible for integration of viral DNA into the host genome, which is the essential step for viral genome replication. We have synthesized a series of five novel isatin derivatives, which possesses anti-HIV activity identified by the in vitro enzyme inhibition study on HIV integrase. Among them, SPIII-5H possesses highest activity with least IC₅₀ value of 3 μ M. In this work, we have predicted the binding modes of isatin derivatives onto the active site of HIV integrase using Glide 5. This docking study shows that critical viral DNA substrate binding residues such as Lys156, Lys159 and Asn155 donates hydrogen bond to compound the active site residues such as Glu 152, Thr66, Ile 151 form hydrophobic interactions. These interactions contribute inhibition activity to the compounds and they share common pharmacophoric features with each other and with available inhibitor 5CITEP. Therefore in this work we propose the pharmacophoric features and bioactive conformation of isatin derivatives and can be used as drug lead for drug designing purpose in the future.

